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Abstract
Purpose: To evaluate the radiographic density and proportion of trabecular bone in the femur 
of female rats treated with glucocorticoid combined or not with bisphosphonate.
Methods: Thirty-six female Wistar rats were allocated to 3 groups: (1) control, (2) glucocorticoid, 
and (3) glucocorticoid + bisphosphonate. Group 1 was given saline solution (subcutaneous 
injections – 2 mL/kg), groups 2 and 3 were given methylprednisolone acetate (1 mg/kg). 
Group 3 also received risedronate (3 mg/kg). The animals were killed and each left femur was 
dissected, radiographed, and histologically processed. A single observer, blind to experimental 
group, measured optical density and the proportion of trabecular bone. Data were analyzed 
using ANOVA and Tukey test (α=5 %).
Results: Radiographic density was lower in group 2 than in groups 1 and 3, which were not 
statistically different. Group 2 had a lower mean proportion of trabecular bone than group 3; 
groups 2 and 3 did not differ from group 1.
Conclusions: These results suggest that administration of bisphosphonate reverses reduction 
in the proportion of trabecular bone resulting from glucocorticoid use, and that it is possible 
to detect these changes with radiography.
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Resumo
Objetivo: Avaliar a densidade radiográfica e a proporção trabecular do fêmur de ratas 
submetidas à administração de glicocorticóide, seguida ou não de bisfosfonato.
Metodologia: Foram utilizadas 36 ratas Wistar, alocadas a três grupos: (1) controle, (2) glico- 
corticóide e (3) glicocorticóide + bisfosfonato. O grupo 1 recebeu injeções subcutâneas (2 mL/kg) 
de solução salina, os grupos 2 e 3 receberam acetato de metilprednisolona (1 mg/kg), sendo 
que o grupo 3 foi tratado adicionalmente com risedronato (3 mg/kg). Os animais foram 
eutanasiados e cada fêmur esquerdo foi dissecado, radiografado e submetido a processamento 
histológico. Um observador, cego para o grupo a que pertencia a imagem, obteve a média de 
densidade óptica e o percentual de trabéculas ósseas por campo. Os dados foram analisados 
por ANOVA, complementada pelo Teste de Tukey (α=5 %).
Resultados:  Houve  médias  menores  de  densidade  radiográfica  no  grupo  2,  diferindo 
significativamente do 1 e do 3, que não diferiram entre si.  Quanto à proporção de trabéculas, 
as médias foram menores no grupo 2, diferindo significativamente do 3; os grupos 2 e 3 não 
diferiram significativamente do grupo 1.
Conclusões:  Os  resultados  sugerem  que  a  administração  de  bisfosfonato  recupera  a 
proporção de trabéculas ósseas diminuídas pela ação do corticóide e estas alterações são 
radiograficamente detectáveis. 
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Introduction
Osteoporosis is defined as a systemic metabolic bone disease, 
characterized by reduced bone mass and microarchitecture 
deterioration with increased bone fragility and susceptibility 
to fractures (1). In the adult bone there is equilibrium between 
bone resorption and formation (turnover), which are related 
by complex biochemical interactions between osteoblast 
and osteoclast activity. Osteoporosis occurs when resorption 
predominates over bone formation (2-5).
Since  few  symptoms  emerge,  osteoporosis  very  often 
manifests as a bone fracture. Femoral fractures are the 
most feared complication of osteoporosis because they 
cause  major  morbidity  (pain,  deformity,  and  physical 
disability) and mortality, with high impact on public health. 
Its incidence has increased all over the world as a result of 
increased population survival and aging (6). According to 
Machado (7), osteoporosis diagnosis is made on the basis 
of clinical history, investigation of predisposing factors, and 
supplemental exams. Conventional radiographs are only 
able to detect bone loss above 30 %. Bone densitometry is 
considered the gold standard for diagnosis and follow-up 
and should be carried out annually or at shorter intervals 
when necessary, for example, when the patient is undergoing 
corticosteroid therapy.
Glucocorticoids are widely used as pharmacological agents 
because of their anti-inflammatory and immunosuppressive 
properties. Among their adverse effects, osteoporosis stands 
as one of the most common sequelae, since glucocorticoids 
reduce osteoblast activity without a compensating reduction 
in bone resorption, with a high risk for fractures. Bone   
loss induced by glucocorticoids primarily affects trabecular 
bone. The mechanism of action includes a reduction in 
absorption of calcium in the intestine and increased renal 
excretion (8-10).
Bisphosphonates are pyrophosphates that inhibit osteoclast 
production or activity and act on osteoblasts and bone 
formation and mineralization. Administered orally, they are 
considered effective both for prevention and for treatment 
of glucocorticoid-induced osteoporosis, with the ability to 
increase bone mass in the spine and femur (8-10).
When studying bone metabolic diseases, in particular of its 
trabeculae, histomorphometry or quantitative histology is 
used. This consists of counting or measuring cell components 
and changes to bone microarchitecture and is the only method 
that allows mineralization and bone formation to be measured, 
especially in osteoporosis induced by glucocorticoids, which 
is characterized by thinning of bone trabeculae (11).
Therefore, the objective of this study was to evaluate the 
radiographic density and proportion of trabecular bone in 
the femurs of rats subjected to glucocorticoid administration, 
followed or not by bisphosphonate use. 
Methodology
This study was approved by the Research Ethics Committee of 
the School of Dentistry, Universidade Federal do Rio Grande 
do Sul, protocol 42/06. All procedures were in accordance with 
international recommendations for research with animals.
Thirty-six female Rattus Norvegicus rats, Wistar strain, were 
obtained from the animal house at the Universidade Luterana 
do Brasil (ULBRA) at 13 weeks’ age and weighing 150 to 
200 g. The rats were identified by colored marks on their 
tails and kept in separate cages, with six rates per cage, in an 
environment with temperature controlled at 23±3ºC, relative 
air humidity of 55±15 %, and a 12 h light-dark cycle. They 
were fed on standard laboratory chow and water ad libitum. 
These rats were allocated to three groups, each containing 12 
animals: 1 - control, 2 - glucocorticoid, and 3 - glucocorticoid + 
bisphosphonate.  The  animals  in  all  three  groups  were 
kept for 12 weeks, during which time group 1 was given 
subcutaneous injections (2 mL/kg) of saline solution three 
times per week. Group 2 were given subcutaneous injections 
of methylprednisolone acetate (1 mg/kg) in suspension and 
diluted in saline solution, three times per week. Group 3 
were given the same treatment as group 2, followed by 
risedronate (3 mg/kg) diluted in distilled water at a volume 
of 5 mL/kg for 12 weeks, six times a week, orally.
The animals in groups 1 and 2 were killed after 12 weeks 
and those in group 3 after 24 weeks. The left femur was 
removed from each animal. The anatomic specimens were 
conditioned individually in labeled plastic pots, containing 
neutral buffered formalin solution at 10 %. The pieces of 
bones were radiographed from the front, with a Dabi Atlante 
(Ribeirão Preto, São Paulo, SP, Brazil) X-ray machine, using 
50 kV, 8 mA, and no. 2 periapical films (Ektaspeed Plus, 
Kodak, Rochester, USA). The locater cylinder of the X-ray 
machine was fitted to a support so that the vertical angle 
was 90° and focal distance was 30 cm, with an exposure 
time of 0.3 s. Films were processed in new solutions, in a 
standardized manner, using the temperature-time method 
(Kodak, Rochester, USA).
All  conventional  X-rays  were  digitized  at  300 dpi  and 
saved in BMP format (Bitmap for Windows) files, which 
were imported into the Adobe Photoshop™ CS software 
(version 7.0, Adobe Systems Inc., San Jose, CA, USA). 
A standardized method was used to select the region of 
interest of each image for optical density analysis. A single 
observer, who was blind to the experimental groups, used 
the histogram function to obtain the mean density of the 
selected area, in pixels (Fig. 1).
Fig. 1. Obtaining values for radiographic density (RD) using the 
software Adobe Photoshop™. The mean and standard deviation 
for the RD of the area selected in the image are shown in the 
histogram window.30  Rev. odonto ciênc. 2009;24(1):28-31
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The samples were decalcified in a 1:1 solution of formic 
acid 50 % and sodium citrate 20 %, at the Oral Pathology 
Laboratory of ULBRA. They were kept immersed in the 
solution, with the substance being replaced daily, throughout 
the decalcification period. The time taken for decalcification 
was  controlled  by  means  of  attempting  to  transfix  the 
specimen  with  a  histological  needle.  The  decalcified 
specimens were processed for setting in paraffin. Three 
semi-sequential sections were taken in the axial direction, 
with a thickness of 4 µm and 1mm apart from each other, 
measuring from the extremity of the previous section, using 
a Leica 2155 rotary microtome. The sections were collected 
on histological slides. The sections were then stained with 
Hematoxylin  and  Eosin  (HE)  for  observation  using  a 
transmitted light microscope.
The center of each histological section was selected, which 
was captured using a microscope at 4X magnification and 
then photographed using a digital camera. The captured 
images were then imported into Adobe Photoshop™. The 
area of trabecular bone observed in each field was quantified, 
with the aim of determining the proportion between the 
area of trabecular bone and marrow space (Fig. 2). The 
Table 1. Comparison between study groups (n=12/group) in terms of radiographic density (in pixels) and 
proportion of trabecular bone (%).
Group Mean* SD 95 % CI F P
Radiographic density
Control 197.24  A 12.39 [189.37 to 205.11] 17.20 <0.01
Glucocorticoid 179.37  B 6.15 [175.45 to 183.27]
Glucocorticoid + Bisphosphonate 199.33  A 7.79 [194.38 to 204.28]
Proportion of trabecular bone
Control 54.96  AB 9.00 [49.24 to 60.67] 4.27 0.02
Glucocorticoid 47.98  A 6.88 [43.61 to 52.35]
Glucocorticoid + Bisphosphonate 58.26  B 10.20 [51.78 to 64.74]
* Means followed by the same letter are not statistically different (ANOVA and Tukey test, α=5 %).
specimens were evaluated in stages: A maximum of ten 
images were evaluated per day and, after a 7-day interval, a 
second evaluation was performed.
Data on density values of the radiographic images and 
proportion of trabecular bone per field were analyzed by 
Analysis of Variance and Tukey’s Multiple Comparisons 
Test, at the significance level of 5 %, using the statistical 
software SPSS, version 10.0.
Results
Significant differences of radiographic density and proportion 
of trabecular bone were found between groups (Table 1). 
Groups 1 (control) and 3 (glucocorticoid + bisphosphonate) 
did  not  differ  but  exhibited  higher  means  of  radio- 
graphic density than group 2 (glucocorticoid) (F=17.20; 
P<0.01). 
For proportion of trabecular bone, Group 3 (glucocorticoid + 
bisphosphonate) showed a significantly higher mean value 
than group 2 (glucocorticoid). Group 1 (control) did not 
differ significantly from either of the other groups (F=4.27; 
P=0.02).
Fig. 2. Selecting trabeculae images and obtaining the trabecular area using the histogram function.  Rev. odonto ciênc. 2009;24(1):28-31  31
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Discussion
This study analyzed the radiographic density and proportion 
of trabecular bone in the femur of female rats medicated with 
glucocorticoid and bisphosphonate, detecting significant 
differences between groups. Administration of high dose 
of glucocorticoids for prolonged periods is associated with 
loss of bone mass, which is more evident and occurs more 
rapidly in trabecular bone (12-16). The dose used in this 
study has previously been employed by Takahashi et al. (9) 
to induce bone loss in female rats, which loss was of the 
order of 6 % compared with a control group and measured 
by bone densitometry of vertebrae. 
The  present  study  showed  that  the  administration  of 
bisphosphonate  was  capable  of  reversing  the  loss  of 
radiographic density resulting from the administration of 
glucocorticoid, leading to a slightly higher proportion of 
trabecular bone than in the control group, confirming previous 
studies (9,15). These results for radiographic density are 
comparable with the findings by Pinto et al. (17), which 
described reduced bone density as a typical radiographic 
feature  of  osteoporosis  induced  by  dexamethasone  and 
increased density in response to administration of sodium 
alendronate. 
The  area  of  trabeculae  in  each  field,  measured  using 
an  image  analysis  software,  was  determined  from  the 
proportion between the area of the trabeculae and the area 
of the marrow space. In relation to group 1 (control), this 
proportion was reduced as a result of the administration of 
glucocorticoid and its increase was related to administration 
of  bisphosphonate,  but  these  differences  did  not  attain 
statistical significance. Statistically significant differences 
were only observed when group 2 (glucocorticoid) was 
compared with group 3 (glucocorticoid + bisphosphonate).   
Pinto et al. (18) used histomorphometric analysis to confirm 
the possibility of inducing osteoporosis by administration of 
glucocorticoid and of recovering bone mass by administration 
of bisphosphonate.  However, these authors used a graticule 
to quantify trabecular bone during histological analysis.
Histomorphometry by counting points was also employed by 
Piai et al. (19). These authors analyzed the quantities of bone 
matrix formed in response to risedronate, in bone repair of 
the tibia of rats with osteopenia. The quantity of neoformed 
bone tissue, in percentage of area, was determined from the 
ratio between the number of dots superimposed on the bone 
matrix and the total number of dots on the grid, indicating 
that treatment with risedronate was ineffective for bone 
repair and confirming that the effect of bisphosphonates is 
dose-dependent. 
Conclusions
These results suggest that the administration of bisphosphonate 
reverses the reduction in the proportion of trabecular bone 
caused by the effect of glucocorticoids. These changes to the 
bone tissues can be detect with radiography.
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